Lynn Canne Bannen

Title: Innovations of Lynn Canne Bannen: Pioneering Research in Immunological Treatments

Introduction: Lynn Canne Bannen is a prominent inventor based in Pacifica, California. She holds a significant patent that contributes to the field of medical science, particularly in the treatment of immunological, inflammatory, and proliferative diseases.

Latest Patents: Lynn has been awarded a patent for the invention titled "[1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators." This patent focuses on innovative compounds that inhibit kinases such as p70S6, Akt-1, and Akt-2. These compounds modulate protein kinase enzymatic activity, impacting cellular activities related to proliferation, differentiation, programmed cell death, migration, chemoinvasion, and metabolism. The invention encompasses the development of compositions containing these compounds, highlighting their usage in treating kinase-dependent diseases and conditions.

Career Highlights: Lynn is affiliated with Exelixis, Inc., a company renowned for its focus on developing innovative therapies for cancer and other diseases. Her work significantly enhances the company’s portfolio in the field of kinase modulation, paving the way for novel therapeutic approaches.

Collaborations: Throughout her career, Lynn has collaborated with notable colleagues such as Ken Rice and Erick Wang. Their combined expertise ensures a robust approach to research and development, fostering advancements in the medical sciences.

Conclusion: Lynn Canne Bannen's contributions through her innovative patent not only showcase her brilliance as an inventor but also highlight the potential impact of her work in treating diseases linked to kinase activity. Her association with Exelixis, Inc., along with her collaborations, is expected to lead to significant breakthroughs in therapeutic treatments, benefiting many individuals facing health challenges.